IVBXF (Innovent Biologics) Insider Ownership: 0.00 % (As of Sep. 15, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

IVBXF Innovent Biologics Inc IVBXF
71 GF Score
Price $12.34
GF Value $13.84
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Innovent Biologics Insider Ownership?

Innovent Biologics IVBXF +4.91% 71 Insider Ownership is 0.00 % as of Sep. 15, 2026. GuruFocus rates IVBXF with a GF Score™ of 71/100 and a GF Value™ of $13.84 (Modestly Undervalued). The stock has 2 warning signs investors should review.

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Innovent Biologics's insider ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Innovent Biologics's Institutional Ownership is 42.26%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Innovent Biologics's Float Percentage Of Total Shares Outstanding is 0.00%.

Innovent Biologics Insider Ownership Historical Data

* Premium members only.

The historical data trend for Innovent Biologics's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Innovent Biologics Insider Ownership Chart

Innovent Biologics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Insider Ownership
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Innovent Biologics Semi-Annual Data
Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Insider Ownership Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
IVBXF
71GF Score
Innovent Biologics Inc IVBXF
Insider Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Innovent Biologics Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.

Frequently Asked Questions Learn more about Insider Ownership →
What does a Insider Ownership of 0.00 % mean?
Innovent Biologics (IVBXF) has a Insider Ownership of 0.00 % as of Sep. 15, 2026. Insider ownership equals the percent of shares owned by company insiders relative to total shares. View historical data on Innovent Biologics and its competitors.
Is Innovent Biologics' Insider Ownership too high?
Innovent Biologics' current Insider Ownership is 0.00 %. Overall, Innovent Biologics has a GF Score™ of 71/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Innovent Biologics' Insider Ownership compare to VRTX and REGN?
Innovent Biologics' Insider Ownership of 0.00 % can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Insider Ownership for a Biotechnology company?
A good Insider Ownership depends on the Biotechnology industry context. However, Insider Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Insider Ownership mean?
A high Insider Ownership can signal that a stock is expensive relative to its fundamentals. Insider ownership equals the percent of shares owned by company insiders relative to total shares. View historical data on Innovent Biologics and its competitors. Innovent Biologics's current Insider Ownership is 0.00 %. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Innovent Biologics stock overvalued right now?
Based on GuruFocus' analysis, Innovent Biologics (IVBXF) is currently considered Modestly Undervalued. The stock's GF Value™ is $13.84, compared to a current price of $12.34 — trading 10.9% below its estimated fair value. The current Insider Ownership is 0.00 %. Innovent Biologics' overall GF Score™ is 71/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Insider Ownership calculated?
Insider Ownership is calculated from a company's financial statements. For Innovent Biologics (IVBXF), the current Insider Ownership is 0.00 % as of Sep. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Innovent Biologics (IVBXF) Overvalued in 2026?

Based on GuruFocus' analysis, Innovent Biologics stock appears to be undervalued. The current stock price of $12.34 is trading 10.9% below its estimated GF Value™ of $13.84. GuruFocus considers Innovent Biologics to be Modestly Undervalued.

Key valuation signals for IVBXF:

  • Insider Ownership: 0.00 %
  • GF Value™: $13.84 vs. price of $12.34 (10.9% below fair value)
  • GF Score™: 71/100 with 2 warning signs

No single metric tells the full story. See the IVBXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Innovent Biologics Business Description

Address 168 Dongping Street, Suzhou Industrial Park, Jiangsu Province, Suzhou, CHN, 215123
Innovent Biologics is one of the leading biotechnology companies in China. Listed on the Hong Kong stock exchange in 2018, Innovent has 12 commercialized oncology products and four commercialized nononcology products as of January 2026, and 34 drugs in its research and development pipeline. Its core assets are Tyvyt, a PD-1 inhibitor included in the National Reimbursement Drug Lists (NRDL) for the first-line treatment of five major cancers, and mazdutide, a GLP-1/glucagon dual agonist drug for weight loss, fat breakdown, and Type 2 diabetes. Mazdutide is the first domestic GLP-1 drug produced and competes with Eli Lilly and Novo Nordisk in China. Tyvyt's main competition includes drugs from Junshi, Jiangsu Hengrui, BeOne, Merck, and Bristol Myers.
71GF Score

Get the complete analysis for IVBXF

Insider Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$12.34
Price
$13.84
GF Value